Description

Maxorif-OZ Tablets | Rifaximin and Ornidazole | Intra Life

Maxorif-OZ is a prescription combination antimicrobial tablet marketed by Intra Life. It contains Rifaximin, a minimally absorbed rifamycin-class antibiotic acting predominantly within the gastrointestinal tract, and Ornidazole, a nitroimidazole antimicrobial active against certain susceptible anaerobic bacteria and protozoa. The ingredients have distinct mechanisms of antimicrobial action.

Clinical use must follow the approved Indian product label and a registered medical practitioner’s assessment. The presence of two antimicrobials does not, by itself, establish efficacy for all types of diarrhoea or gastrointestinal infection.

Composition and mechanism of action

Step 1: Rifaximin interferes with synthesis of bacterial RNA in susceptible organisms.

Step 2: Ornidazole produces DNA damage in susceptible anaerobic bacteria and protozoa.

Step 3: The appropriate clinical application of the combination depends on microbiology, approved indication, dose and patient factors. No additive clinical benefit should be claimed without supporting evidence..

Indications and treatment context

Rifaximin and Ornidazole individually have approved uses in selected infectious conditions; however, the approved indications of this particular fixed-dose combination have not been independently verified. Avoid presenting individual-ingredient indications as approved Maxorif-OZ uses.

• Potential medical-information topics: selected gastrointestinal bacterial infections, certain protozoal infections, and infections caused by susceptible anaerobic microorganisms.
• Not every case of diarrhoea requires an antimicrobial. Hydration, medical evaluation and pathogen-specific treatment may be more appropriate.
• The carton does not display individual ingredient strengths; verify strengths and fixed-dose-combination approval before publishing indication-specific claims.

Dosage, administration and precautions

• Dosage and duration: strictly as prescribed by a registered medical practitioner according to the approved label and confirmed formulation strength.
• Administration with meals: follow the product insert or prescriber’s directions.
• Missed dose: ask a pharmacist or follow approved instructions; do not double a dose.
• Avoid self-treatment of nonspecific diarrhoea, abdominal pain or indigestion with antimicrobial combinations.
• Possible adverse reactions include nausea, abdominal discomfort, dizziness, headache and hypersensitivity. Important risks include antibiotic-associated diarrhoea and rare nitroimidazole-related neurological toxicity.
• Pregnancy, liver disease, concomitant medicines and relevant drug interactions require clinician review.

Packaging and product-page specifications

FAQ

What is Maxorif-OZ?
A prescription combination tablet containing Rifaximin and Ornidazole, marketed by Intra Life.

Is Maxorif-OZ an antibiotic?
It contains Rifaximin (an antibiotic) and Ornidazole (a nitroimidazole antimicrobial).

Can it be taken for loose motions?
Not without clinical assessment. Many cases of loose motions do not require antibiotics, and the approved combination indication must be verified.

How does Rifaximin work?
It inhibits bacterial RNA synthesis through bacterial DNA-dependent RNA polymerase.

How does Ornidazole work?
It damages DNA in susceptible anaerobic organisms and certain protozoa.

What is the carton size?
10 x 10 tablets, or 100 tablets total.

Keywords